• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs - Real World Outcomes >Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices
【24h】

Comparison of Two Corticosteroid Pre-Infusion Regimens for Pegloticase in the United States: A Retrospective Analysis in Community Rheumatology Practices

机译：两种皮质类固醇预输注方案对美国Pegliticase的比较：社区风湿病学实践的回顾性分析

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BackgroundPegloticase is a recombinant porcine-like uricase enzyme that is FDA-approved for the treatment of chronic refractory gout in adults. Some patients receiving pegloticase develop anti-drug antibodies, which leads to both loss of pegloticase efficacy and an increased risk for infusion reactions. In the pivotal trials, all patients received pre-infusion medications before each pegloticase dose, including intravenous (IV) hydrocortisone. In clinical practice, many clinicians use methylprednisolone for pre-infusion therapy with pegloticase; however, the efficacy of methylprednisolone compared with hydrocortisone as a pre-infusion medication for pegloticase has not been established. ObjectiveThe aim of this study was to compare the efficacy of methylprednisolone versus hydrocortisone as a pre-infusion medication for pegloticase. MethodsData were retrospectively collected from 92 qualifying patients treated with pegloticase and administered pre-infusion prophylaxis with either intravenous hydrocortisone or methylprednisolone. Patient demographics, steroid type and dose, duration of pegloticase therapy, overall number of infusions, and number of infusion reactions were assessed. ResultsPatients treated with methylprednisolone as a pre-infusion medication received on average 8.5 pegloticase infusions versus 4.9 infusions for patients who were treated with hydrocortisone ( p ConclusionIn this retrospective chart-review project, patients were able to have a longer duration of pegloticase therapy, received a significantly greater number of infusions, and experienced fewer infusion reactions when methylprednisolone was used as the corticosteroid for pre-infusion prophylaxis compared with hydrocortisone.
机译：BackgroundPegloticase是一种重组猪状尿酶酶，即FDA批准用于治疗成人中的慢性耐火痛风。一些接受Pegloticase的患者发育抗药物抗体，这导致Pegloticase疗效的丧失和输注反应的风险增加。在关键试验中，所有患者均在每种Pegloticase剂量之前接受预输注药物，包括静脉内（IV）氢化胞蔻体。在临床实践中，许多临床医生使用甲基己酮用于用Pegliticase进行预输注治疗;然而，与氢化氨酮相比，甲基己酮醇与氢化酶作为PEGLICALS的预输注药物相比的疗效。本研究的目的是将甲基己二龙酮与氢化子酮的疗效进行比较，作为Pegloticase的预输注药物。方法从用Pegloticase治疗的92名符合患者回顾性地收集，并用静脉内氢化酮或甲基己酮酮施用预防预防预防预防。评估患者人口统计学，类固醇类型和剂量，佩格拉洛酶治疗的持续时间，输注总数和输注反应数。用甲基己酮酮作为含有氢化胞嘧啶处理的患者的预输注药物治疗的结果含量为8.5蛋白的输注（P结论在此回顾性图表审查项目，患者能够具有较长的Pegloticase疗法，接受了当与氢化胞蔻体相比，当使用甲基己酮醇醚作为皮质类固醇时，输注次数较多，并且由于甲基己酮酮作为皮质类固醇而经历了较少的输注反应。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号